Sandoz moves two new biosimilars into PhIII; Neurocrine plans to raise $77M;

@FierceBiotech: Scientists balk as U.S. gov't pushes limits to bird #flu discourse. Article | Follow @FierceBiotech

@JohnCFierce: Just about everybody expected dapagliflozin to get batted down; but the rejection also spells trouble for other SGLT2 inhibitors. | Follow @JohnCFierce

@RyanMFierce: Hmm. Is it realistic for Obama to set a 2025 goal for effective ways to treat and prevent Alzheimer's? More | Follow @RyanMFierce

@FierceMedDev: Covidien gives update on voluntary recall of BIS bilateral sensors. Release | Follow @FierceMedDev

> Sandoz says it has launched two new late-stage studies aim at advancing biosimilar competitors to Amgen's Neulasta and Neupogen. "Sandoz is already the clear global leader in biosimilars overall and in each of our three marketed products, with approximately 50% total segment share in the highly regulated markets of North America, Europe, Japan and Australia," said Sandoz's global head, Jeff George. Release

> Neurocrine Biosciences is planning a $77 million stock offering. Story

> When Roche's melanoma drug Zelboraf won the FDA's nod in August, it became the first therapy for the disease targeted at patients with a particular genetic abnormality. Scientists now have found another genetic link that stands to affect how Zelboraf is used: Patients with RAS mutations appear to be susceptible to accelerated growth of secondary skin cancers. Report

> Gilead has won FDA approval to use the HIV drug Viread with other antivirals in children aged 2 to 12. Story

Pharma News

@FiercePharma: Interesting executive interview/analysis of Cipla's management tweaks, efforts to jump start exports--ET. Article | Follow @FiercePharma

> No more working Saturdays at exports-minded Cipla. Item

> Pharma gets its close-up in new Hollywood films. Report

> AZ chief: Emerging markets are tougher than you think. Item

> Adding MEK drug to Zelboraf could stymie secondary cancers. Story

Vaccines News

> Novartis' meningitis B vaccine aces study en route to market. News

> Breast cancer vaccine set for large-scale testing. Story

> Flu season gets off to a sluggish start. More

> Paragon nabs $15M filovirus vax contract from DoD. Item

> Confident Inovio chief pushes ahead on universal flu vaccine. Article

Pharma Manufacturing News

> Bioprocess budget hikes a sign of efficiency quest. Report

> Genzyme revives Fabrazyme with EMA plant OK. News

> Congresswoman: Novartis troubles call for more FDA oversight. Item

> Novartis, Lundbeck score wins for manufacturing in the West. Article

And Finally... We all know that just looking at pictures of food can make us hungry. Now Max Planck researchers have documented that the amount of the neurosecretory protein hormone ghrelin in the blood increases as a result of visual stimulation through images of food. News

Suggested Articles

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.

The biotech began testing the small molecule in a phase 3 trial of heavily pretreated small cell lung cancer patients late last year. 

Roche is spending up to $1.4 billion to snap up a scarring-focused biotech, nabbing an FDA breakthrough-tagged therapy in the process.